ID28735A - Sediaan farmasi pelepasan terkendali satuan ganda yang bebas dan proses pembuatennya - Google Patents

Sediaan farmasi pelepasan terkendali satuan ganda yang bebas dan proses pembuatennya

Info

Publication number
ID28735A
ID28735A IDW20010651A ID20010651A ID28735A ID 28735 A ID28735 A ID 28735A ID W20010651 A IDW20010651 A ID W20010651A ID 20010651 A ID20010651 A ID 20010651A ID 28735 A ID28735 A ID 28735A
Authority
ID
Indonesia
Prior art keywords
pharmaceutical
production process
double unit
preservation under
free double
Prior art date
Application number
IDW20010651A
Other languages
English (en)
Inventor
Venkata-Rangarao Kanikanti
Roland Rupp
Erich Brendel
Claus Weisemann
Ernst Chantraine
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of ID28735A publication Critical patent/ID28735A/id

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Nonmetallic Welding Materials (AREA)
IDW20010651A 1998-09-18 1999-09-17 Sediaan farmasi pelepasan terkendali satuan ganda yang bebas dan proses pembuatennya ID28735A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19842753A DE19842753A1 (de) 1998-09-18 1998-09-18 Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
ID28735A true ID28735A (id) 2001-06-28

Family

ID=7881376

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20010651A ID28735A (id) 1998-09-18 1999-09-17 Sediaan farmasi pelepasan terkendali satuan ganda yang bebas dan proses pembuatennya

Country Status (29)

Country Link
US (1) US6805881B1 (id)
EP (1) EP1113787B1 (id)
JP (1) JP2002526437A (id)
KR (1) KR100660072B1 (id)
CN (1) CN1178650C (id)
AT (1) ATE260645T1 (id)
AU (2) AU5861499A (id)
BG (1) BG105325A (id)
BR (1) BR9913839A (id)
CA (1) CA2344372C (id)
DE (2) DE19842753A1 (id)
DK (1) DK1113787T3 (id)
EE (1) EE04700B1 (id)
ES (1) ES2215404T3 (id)
HK (1) HK1040932B (id)
HR (1) HRP20010198A2 (id)
HU (1) HUP0103669A3 (id)
ID (1) ID28735A (id)
IL (2) IL141532A0 (id)
NO (1) NO20011211L (id)
NZ (1) NZ510563A (id)
PL (1) PL195543B1 (id)
PT (1) PT1113787E (id)
RU (1) RU2235540C2 (id)
SK (1) SK285099B6 (id)
TR (1) TR200100756T2 (id)
UA (1) UA73097C2 (id)
WO (2) WO2000016747A1 (id)
ZA (1) ZA200101485B (id)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
AR034813A1 (es) 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
DE10300111A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
AU2005320547B2 (en) 2004-12-27 2009-02-05 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
EP1685841A1 (en) * 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005012561B4 (de) 2005-03-18 2008-06-19 Christian Beer Verfahren zum Betrieb eines Werkstück-Transfersystems
DE102005045518A1 (de) * 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
SG166126A1 (en) 2005-10-04 2010-11-29 Bayer Schering Pharma Ag Novel polymorphous form and the amorphous form of 5-chloro-n-({(5s)-2-oxo- 3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
CN100448432C (zh) * 2006-10-26 2009-01-07 徐竹青 高溶出度尼莫地平分散片的制备方法
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
US7952167B2 (en) * 2007-04-27 2011-05-31 Taiwan Semiconductor Manufacturing Company, Ltd. Scribe line layout design
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
AR075179A1 (es) * 2009-01-28 2011-03-16 Novartis Ag Formulaciones galenicas de compuestos organicos que comprenden alisquireno
US20100247646A1 (en) * 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Extended release tablets of nisoldipine
TR201802207T4 (tr) 2010-03-29 2018-03-21 Astellas Pharma Inc Kontrollü Salımlı Farmasötik Bileşim.
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5482525A (en) 1977-12-13 1979-06-30 Aisan Ind Co Ltd Exhaust gas recirculation system
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4449983A (en) 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
DE3612211A1 (de) 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
DE3720757A1 (de) 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
DE3830353A1 (de) 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
JPH03145418A (ja) 1989-10-27 1991-06-20 Sumitomo Pharmaceut Co Ltd 塩基性薬物塩酸塩の徐放性製剤
EP0580860B2 (en) 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Method of manufacturing solid dispersion
DE4138513A1 (de) 1991-11-23 1993-05-27 Basf Ag Feste pharmazeutische retardform
DE4413350A1 (de) 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
SE9402422D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
FR2725624B1 (fr) 1994-10-14 1997-01-17 Jouveinal Inst Rech Procede de preparation de formes pharmaceutiques a liberation controlee
DE19504831A1 (de) 1995-02-14 1996-09-05 Basf Ag Feste Wirkstoffzubereitungen enthaltend Hydroxypropylcellulose

Also Published As

Publication number Publication date
EP1113787A1 (de) 2001-07-11
PL195543B1 (pl) 2007-09-28
CN1317959A (zh) 2001-10-17
DE59908764D1 (de) 2004-04-08
CA2344372C (en) 2009-12-22
AU5861499A (en) 2000-04-10
PL346535A1 (en) 2002-02-11
US6805881B1 (en) 2004-10-19
DK1113787T3 (da) 2004-05-17
UA73097C2 (en) 2005-06-15
SK285099B6 (sk) 2006-06-01
JP2002526437A (ja) 2002-08-20
IL141532A (en) 2007-03-08
WO2000016747A1 (de) 2000-03-30
IL141532A0 (en) 2002-03-10
WO2000016748A1 (de) 2000-03-30
SK3722001A3 (en) 2001-10-08
CA2344372A1 (en) 2000-03-30
PT1113787E (pt) 2004-07-30
BR9913839A (pt) 2001-06-12
EE200100161A (et) 2002-08-15
HK1040932B (zh) 2005-08-05
AU750617B2 (en) 2002-07-25
ZA200101485B (en) 2002-02-22
NZ510563A (en) 2002-10-25
HK1040932A1 (en) 2002-06-28
RU2235540C2 (ru) 2004-09-10
KR20010073172A (ko) 2001-07-31
EE04700B1 (et) 2006-10-16
DE19842753A1 (de) 2000-03-23
CN1178650C (zh) 2004-12-08
BG105325A (bg) 2001-11-30
ES2215404T3 (es) 2004-10-01
ATE260645T1 (de) 2004-03-15
KR100660072B1 (ko) 2006-12-22
HRP20010198A2 (en) 2002-04-30
AU6191899A (en) 2000-04-10
HUP0103669A3 (en) 2006-07-28
NO20011211D0 (no) 2001-03-09
EP1113787B1 (de) 2004-03-03
HUP0103669A2 (hu) 2002-01-28
TR200100756T2 (tr) 2001-07-23
NO20011211L (no) 2001-03-09

Similar Documents

Publication Publication Date Title
ID28735A (id) Sediaan farmasi pelepasan terkendali satuan ganda yang bebas dan proses pembuatennya
CA2307018A1 (en) Osmotic medicament releasing system
AU7143796A (en) Controlled release matrix for pharmaceuticals
CA2265766A1 (en) Rapidly disintegrating pellets
BR9506029A (pt) Forma farmaêutica oral de múltipla dosagem unitária em tablete processo para a preparação da mesma para a inibição da secreção de ácido gástrico em mamiferos e no homem para o tratamento de doenças inflamatórias gastrointestinais em maniferos e no homem e embalgem de ampola de pressão transversal
BR9612291A (pt) Forma de dosagem sólida bioadesiva
CA2322644A1 (en) Pharmaceutical composition of topiramate
FI20011852A (fi) Menetelmä fluoksetiinia tai sen happoadditiosuolaa sisältävän dispergoituvan tabletin valmistamiseksi
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
MX9602683A (es) Compuestos de 6-dimetilaminometil-1-fenil-ciclohexano como substancias farmaceuticamente activas.
ATE100708T1 (de) Unbeschichtete pharmazeutische reaktionstablette.
AU3533395A (en) Oral sustained-release preparation
CA2150184A1 (en) Pharmaceutical composition for the treatment of inflammatory bowel diseases
EP1622586A4 (en) METHOD FOR PRODUCING TANNATE TABLETS, CAPSULES OR OTHER SOLID DOSAGE FORMS
FR2698788B1 (fr) Composition pharmaceutique effervescente contenant de l'ibuprofène et son procédé de préparation.
ES2131318T3 (es) Pelets.
GR3018685T3 (en) Method for the manufacture of a controlled release solid unit dosage form.
CA2150183A1 (en) Pharmaceutical composition for the treatment of hemorrhoidal diseases
GB2282758A (en) Oral morphine-6-glucuronide compositions
NZ502807A (en) Preparation of solid oral dosage forms of alendronic acid (4-amino-1-hydroxybutylidene-1, 1-bisphosphonic acid)
AU7000994A (en) Phosphosuccinic acid derivatives and their use as medicaments
UA23363A (uk) Спосіб лікування запальних процесів придатків матки
CA2250115A1 (en) Fast disintegrating oral dosage form